Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Effect of aspirin on disability-free survival in the healthy elderly

    Access Status
    Fulltext not available
    Authors
    McNeil, J.
    Woods, R.
    Nelson, M.
    Reid, Christopher
    Kirpach, B.
    Wolfe, R.
    Storey, E.
    Shah, R.
    Lockery, J.
    Tonkin, A.
    Newman, A.
    Williamson, J.
    Margolis, K.
    Ernst, M.
    Abhayaratna, W.
    Stocks, N.
    Fitzgerald, S.
    Orchard, S.
    Trevaks, R.
    Beilin, L.
    Donnan, G.
    Gibbs, P.
    Johnston, C.
    Ryan, J.
    Radziszewska, B.
    Grimm, R.
    Murray, A.
    Date
    2018
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    McNeil, J. and Woods, R. and Nelson, M. and Reid, C. and Kirpach, B. and Wolfe, R. and Storey, E. et al. 2018. Effect of aspirin on disability-free survival in the healthy elderly. New England Journal of Medicine. 379 (16): pp. 1499-1508.
    Source Title
    New England Journal of Medicine
    DOI
    10.1056/NEJMoa1800722
    ISSN
    0028-4793
    School
    School of Public Health
    URI
    http://hdl.handle.net/20.500.11937/74488
    Collection
    • Curtin Research Publications
    Abstract

    Background: Information on the use of aspirin to increase healthy independent life span in older persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend disabilityfree life in healthy seniors is unclear. Methods: From 2010 through 2014, we enrolled community-dwelling persons in Australia and the United States who were 70 years of age or older (or =65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or physical disability. Participants were randomly assigned to receive 100 mg per day of enteric-coated aspirin or placebo orally. The primary end point was a composite of death, dementia, or persistent physical disability. Secondary end points reported in this article included the individual components of the primary end point and major hemorrhage. Results: A total of 19,114 persons with a median age of 74 years were enrolled, of whom 9525 were randomly assigned to receive aspirin and 9589 to receive placebo. A total of 56.4% of the participants were women, 8.7% were nonwhite, and 11.0% reported previous regular aspirin use. The trial was terminated at a median of 4.7 years of follow-up after a determination was made that there would be no benefit with continued aspirin use with regard to the primary end point. The rate of the composite of death, dementia, or persistent physical disability was 21.5 events per 1000 person-years in the aspirin group and 21.2 per 1000 person-years in the placebo group (hazard ratio, 1.01; 95% confidence interval [CI], 0.92 to 1.11; P = 0.79). The rate of adherence to the assigned intervention was 62.1% in the aspirin group and 64.1% in the placebo group in the final year of trial participation. Differences between the aspirin group and the placebo group were not substantial with regard to the secondary individual end points of death from any cause (12.7 events per 1000 person-years in the aspirin group and 11.1 events per 1000 person-years in the placebo group), dementia, or persistent physical disability. The rate of major hemorrhage was higher in the aspirin group than in the placebo group (3.8% vs. 2.8%; hazard ratio, 1.38; 95% CI, 1.18 to 1.62; P<0.001). Conclusions: Aspirin use in healthy elderly persons did not prolong disability-free survival over a period of 5 years but led to a higher rate of major hemorrhage than placebo.

    Related items

    Showing items related by title, author, creator and subject.

    • Effect of aspirin on all-cause mortality in the healthy elderly
      McNeil, J.; Nelson, M.; Woods, R.; Lockery, J.; Wolfe, R.; Reid, Christopher; Kirpach, B.; Shah, R.; Ives, D.; Storey, E.; Ryan, J.; Tonkin, A.; Newman, A.; Williamson, J.; Margolis, K.; Ernst, M.; Abhayaratna, W.; Stocks, N.; Fitzgerald, S.; Orchard, S.; Trevaks, R.; Beilin, L.; Donnan, G.; Gibbs, P.; Johnston, C.; Radziszewska, B.; Grimm, R.; Murray, A. (2018)
      Background: In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary ...
    • Effect of aspirin on cardiovascular events and bleeding in the healthy elderly
      McNeil, J.; Wolfe, R.; Woods, R.; Tonkin, A.; Donnan, G.; Nelson, M.; Reid, Christopher; Lockery, J.; Kirpach, B.; Storey, E.; Shah, R.; Williamson, J.; Margolis, K.; Ernst, M.; Abhayaratna, W.; Stocks, N.; Fitzgerald, S.; Orchard, S.; Trevaks, R.; Beilin, L.; Johnston, C.; Ryan, J.; Radziszewska, B.; Jelinek, M.; Malik, M.; Eaton, C.; Brauer, D.; Cloud, G.; Wood, E.; Mahady, S.; Satterfield, S.; Grimm, R.; Murray, A. (2018)
      Background: Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. However, its role in the primary prevention of cardiovascular disease is unclear, especially in older persons, who ...
    • Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial
      Berk, M.; Berk, M.; Woods, R.L.; Nelson, M.R.; Shah, R.C.; Reid, C.M.; Reid, Christopher ; Storey, E.; Fitzgerald, S.; Lockery, J.E.; Wolfe, R.; Mohebbi, M.; Mohebbi, M.; Dodd, S.; Murray, A.M.; Stocks, N.; Fitzgerald, P.B.; Mazza, C.; Agustini, B.; McNeil, J.J. (2020)
      © 2020 American Medical Association. All rights reserved. Importance: Depression is associated with increased inflammation, which may precede its onset, especially in older people. Some preclinical data suggest potential ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.